Views of health professionals on risk-based breast cancer screening and its implementation in the Spanish National Health System: A qualitative discussion group study.
Adult
Aged
Attitude of Health Personnel
Breast Neoplasms
/ diagnosis
Decision Support Techniques
Early Detection of Cancer
/ methods
Female
Focus Groups
Health Personnel
Health Services Accessibility
Humans
Mass Screening
/ methods
Middle Aged
Patient Acceptance of Health Care
Qualitative Research
Risk
Risk Assessment
Spain
State Medicine
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
07
2021
accepted:
26
01
2022
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
17
3
2022
Statut:
epublish
Résumé
With the aim of increasing benefits and decreasing harms, risk-based breast cancer screening has been proposed as an alternative to age-based screening. This study explores barriers and facilitators to implementing a risk-based breast cancer screening program from the perspective of health professionals, in the context of a National Health Service. Socio-constructivist qualitative research carried out in Catalonia (Spain), in the year 2019. Four discussion groups were conducted, with a total of 29 health professionals from primary care, breast cancer screening programs, hospital breast units, epidemiology units, and clinical specialties. A descriptive-interpretive thematic analysis was performed. Identified barriers included resistance to reducing the number of screening exams for low-risk women; resistance to change for health professionals; difficulties in risk communication; lack of conclusive evidence of the benefits of risk-based screening; limited economic resources; and organizational transformation. Facilitators include benefits of risk-based strategies for high and low-risk women; women's active role in their health care; proximity of women and primary care professionals; experience of health professionals in other screening programs; and greater efficiency of a risk-based screening program. Organizational and administrative changes in the health system, commitment by policy makers, training of health professionals, and educational interventions addressed to the general population will be required. Despite the expressed difficulties, participants supported the implementation of risk-based screening. They highlighted its benefits, especially for women at high risk of breast cancer and those under 50 years of age, and assumed a greater efficiency of the risk-based program compared to the aged-based one. Future studies should assess the efficiency and feasibility of risk-based breast cancer screening for its transfer to clinical practice.
Sections du résumé
BACKGROUND
With the aim of increasing benefits and decreasing harms, risk-based breast cancer screening has been proposed as an alternative to age-based screening. This study explores barriers and facilitators to implementing a risk-based breast cancer screening program from the perspective of health professionals, in the context of a National Health Service.
METHODS
Socio-constructivist qualitative research carried out in Catalonia (Spain), in the year 2019. Four discussion groups were conducted, with a total of 29 health professionals from primary care, breast cancer screening programs, hospital breast units, epidemiology units, and clinical specialties. A descriptive-interpretive thematic analysis was performed.
RESULTS
Identified barriers included resistance to reducing the number of screening exams for low-risk women; resistance to change for health professionals; difficulties in risk communication; lack of conclusive evidence of the benefits of risk-based screening; limited economic resources; and organizational transformation. Facilitators include benefits of risk-based strategies for high and low-risk women; women's active role in their health care; proximity of women and primary care professionals; experience of health professionals in other screening programs; and greater efficiency of a risk-based screening program. Organizational and administrative changes in the health system, commitment by policy makers, training of health professionals, and educational interventions addressed to the general population will be required.
CONCLUSIONS
Despite the expressed difficulties, participants supported the implementation of risk-based screening. They highlighted its benefits, especially for women at high risk of breast cancer and those under 50 years of age, and assumed a greater efficiency of the risk-based program compared to the aged-based one. Future studies should assess the efficiency and feasibility of risk-based breast cancer screening for its transfer to clinical practice.
Identifiants
pubmed: 35120169
doi: 10.1371/journal.pone.0263788
pii: PONE-D-21-21753
pmc: PMC8815913
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0263788Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Prev Med. 2018 Nov;116:40-50
pubmed: 30172799
J Wound Ostomy Continence Nurs. 2006 Sep-Oct;33(5):478-81
pubmed: 17133134
Best Pract Res Clin Obstet Gynaecol. 2020 May;65:3-17
pubmed: 31848103
Cancers (Basel). 2021 Aug 18;13(16):
pubmed: 34439302
Breast Cancer Res. 2020 Feb 17;22(1):21
pubmed: 32066492
Cancer. 2014 Oct 1;120(19):2955-64
pubmed: 24830599
BMC Med Inform Decis Mak. 2018 Dec 17;18(1):134
pubmed: 30558581
Breast. 2015 Jun;24(3):237-41
pubmed: 25708717
J Gen Intern Med. 2018 Nov;33(11):1905-1912
pubmed: 30066118
BMC Cancer. 2020 Oct 6;20(1):965
pubmed: 33023516
Clin Breast Cancer. 2019 Aug;19(4):246-253.e2
pubmed: 31072694
Br J Cancer. 2016 Apr 26;114(9):1045-52
pubmed: 27022688
BMJ Open. 2020 Dec 23;10(12):e044597
pubmed: 33361170
Eur J Cancer Care (Engl). 2017 May;26(3):
pubmed: 28145105
Cancer Prev Res (Phila). 2018 May;11(5):255-264
pubmed: 29661853
Eur J Public Health. 2005 Aug;15(4):355-60
pubmed: 15975955
PLoS One. 2018 Jun 1;13(6):e0197772
pubmed: 29856760
Patient Educ Couns. 2021 Aug;104(8):1933-1944
pubmed: 33581968
Qual Health Res. 2015 Sep;25(9):1212-22
pubmed: 26184336
J Public Health (Oxf). 2014 Jun;36(2):285-91
pubmed: 23986542
Psychooncology. 2019 May;28(5):1056-1062
pubmed: 30848018
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS One. 2019 Jul 3;14(7):e0218821
pubmed: 31269051
J Natl Cancer Inst. 2021 Sep 4;113(9):1168-1176
pubmed: 33769540
JAMA Netw Open. 2021 Aug 2;4(8):e2119084
pubmed: 34347061
BMC Cancer. 2020 Mar 24;20(1):247
pubmed: 32209062
PLoS One. 2014 Feb 03;9(2):e86858
pubmed: 24498285
Breast Cancer Res. 2019 May 22;21(1):68
pubmed: 31118087
Rev Peru Med Exp Salud Publica. 2013 Oct-Dec;30(4):691-7
pubmed: 24448951
AMIA Annu Symp Proc. 2015 Nov 05;2015:1352-60
pubmed: 26958276
Ann Oncol. 2010 May;21 Suppl 3:iii43-51
pubmed: 20427360
Patient Educ Couns. 2008 Dec;73(3):526-35
pubmed: 18752915
Genet Med. 2009 Oct;11(10):735-41
pubmed: 19661809
Dimens Crit Care Nurs. 2017 Jul/Aug;36(4):253-263
pubmed: 28570380
Public Health Genomics. 2013;16(3):94-9
pubmed: 23363703
Breast Cancer Res Treat. 2016 Oct;159(3):513-25
pubmed: 27565998
PLoS One. 2019 Dec 16;14(12):e0226352
pubmed: 31841563
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
Public Health Rev. 2019 Feb 28;40:2
pubmed: 30858992
Br J Radiol. 2019 Nov;92(1103):20190660
pubmed: 31538501
Sante Publique. 2016 May-Jun;28(3):353-61
pubmed: 27531433
Public Health Genomics. 2018;21(1-2):37-44
pubmed: 30223261
Healthc Policy. 2019 Nov;15(2):39-54
pubmed: 32077844
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
Int J Cancer. 2021 Apr 12;:
pubmed: 33844853
Breast J. 2010 Jan-Feb;16(1):38-47
pubmed: 19889168
Med Decis Making. 2010 Nov-Dec;30(6):701-11
pubmed: 21088131
Cochrane Database Syst Rev. 2018 Jul 19;7:CD006732
pubmed: 30025154
Breast. 2018 Jun;39:24-32
pubmed: 29529454
Breast Cancer Res Treat. 2019 Jul;176(1):141-148
pubmed: 30941651
BMC Cancer. 2020 May 20;20(1):452
pubmed: 32434564
BMC Cancer. 2020 Jun 18;20(1):570
pubmed: 32552763
Aten Primaria. 2020 Nov;52 Suppl 2:44-69
pubmed: 33388117
BMC Cancer. 2020 Jul 22;20(1):680
pubmed: 32698780